metricas

Vacunas

Sugerencias
Vacunas Analysis of SARS-CoV-2 mutations in the main viral protease (NSP5) and its impli...
Información de la revista
Vol. 23. Núm. S1.
Vacunación COVID-19: Conocimientos y actitudes COVID-19 immunization: Knowledge and attitudes
Páginas S1-S72 Páginas 68-70 (Mayo 2022)
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
3567
Vol. 23. Núm. S1.
Vacunación COVID-19: Conocimientos y actitudes COVID-19 immunization: Knowledge and attitudes
Páginas S1-S72 Páginas 68-70 (Mayo 2022)
Original article

Analysis of SARS-CoV-2 mutations in the main viral protease (NSP5) and its implications on the vaccine designing strategies

Análisis de las mutaciones del SARS-CoV-2 en la principal proteasa viral (NSP5) y sus implicaciones en las estrategias de diseño de vacunas
Visitas
3567
Niti Yashvardhinia, Amit Kumarb, Deepak Kumar Jhac,
,1
a Department of Microbiology, Patna Women's College, Patna 800 001, India
b Department of Botany, Patna University, Patna 800 005, India
c Department of Zoology, P. C. Vigyan Mahavidyalaya, J. P. University, Chapra 841 301, India
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Suplemento especial
Este artículo forma parte de:
Vol. 23. Núm S1

Vacunación COVID-19: Conocimientos y actitudes COVID-19 immunization: Knowledge and attitudes

Más datos
Abstract

SARS-CoV-2 (Severe Acute Respiratory Syndrome), an etiolating agent of novel COVID-19 (coronavirus 2019) pandemic, rapidly spread worldwide, creating an unprecedented public health crisis globally. NSP5, the main viral protease, is a highly conserved protein, encoded by the genome of SARS-CoV-2 and plays an important role in the viral replication cycle. In the present study, we detected a total of 33 mutations from 675 sequences submitted from India in the month of March 2020 to April 2021. Out of 33 mutations, we selected 8 frequent mutations (K236R, N142L, K90R, A7V, L75F, C22N, H246Y and I43V) for further analysis. Subsequently, protein models were constructed, revealing significant alterations in the 3-D structure of NSP5 protein when compared to the wild type protein sequence which also altered the secondary structure of NSP5 protein. Further, we identified 9 B-cell, 10 T-cell and 6 MHC-I promising epitopes using predictive tools of immunoinformatics, out of these epitopes some were non-allergenic as well as highly immunogenic. Results of our study, however, revealed that 10 B-cell epitopes reside in the mutated region of NSP5. Additionally, hydrophobicity, physiochemical properties, toxicity and stability of NSP5 protein were estimated to demonstrate the specificity of the multiepitope candidates. Taken together, variations arising as a consequence of multiple mutations may cause alterations in the structure and function of NSP5 which generate crucial insights to better understand structural aspects of SARS-CoV-2. Our study also revealed, NSP5, a main protease, can be a potentially good target for the design and development of vaccine candidate against SARS-CoV-2.

Palabras clave:
SARS-CoV-2
Pandemia
Epítopos
NSP5
Mutación
Vacuna
Resumen

El SARS-CoV-2 (Síndrome Respiratorio Agudo Severo), un agente etiológico de la nueva pandemia de COVID-19 (coronavirus 2019), se propagó rápidamente por todo el mundo y creó una crisis de salud pública sin precedentes a nivel mundial. El NSP5, la proteasa viral principal, es una proteína altamente conservada, codificada por el genoma del SARS-CoV-2 y juega un papel importante en el ciclo de replicación viral. En el presente estudio se detectaron un total de 33 mutaciones de 675 secuencias presentadas desde la India en el mes de marzo de 2020 a abril de 2021. De 33 mutaciones, se seleccionaron 8 mutaciones frecuentes (K236R, N142L, K90R, A7V, L75F, C22N, H246Y e I43V) para su posterior análisis. Posteriormente, se construyeron modelos proteicos que revelaron alteraciones significativas en la estructura 3D de las proteínas NSP5 en comparación con la secuencia de proteínas de tipo silvestre que también alteraron la estructura secundaria de la proteína NSP5. Además, se identificaron 9 epítopos prometedores de células B, 10 de células T y 6 de MHC-I, utilizando herramientas predictivas de inmunoinformática, algunos no alergénicos y altamente inmunogénicos. Los resultados de nuestro estudio, sin embargo, revelaron que 10 epítopos de células B residen en la región mutada de NSP5. Adicionalmente, se estimó la hidrofobicidad, propiedades fisicoquímicas, toxicidad y estabilidad de la proteína NSP5 para demostrar la especificidad de los candidatos multiepítopos. En conjunto, las variaciones que surgen como consecuencia de múltiples mutaciones pueden causar alteraciones en la estructura y función del NSP5 que generan conocimientos cruciales para entender mejor los aspectos estructurales del SARS-CoV-2. Nuestro estudio también reveló que el NSP5, una proteasa principal, puede ser un blanco potencialmente bueno para el diseño y desarrollo de la vacuna candidata contra el SARS-CoV-2.

Artículo

Opciones para acceder a los textos completos de la publicación Vacunas
Suscriptor
Suscriptor de la revista

Si ya tiene sus datos de acceso, clique aquí.

Si olvidó su clave de acceso puede recuperarla clicando aquí y seleccionando la opción "He olvidado mi contraseña".
Comprar
Comprar acceso al artículo

Comprando el artículo el PDF del mismo podrá ser descargado

Comprar ahora
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
References
[1.]
R. Lu, X. Zhao, J. Li, et al.
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.
The Lancet, 395 (2020), pp. 565-574
[2.]
N. Zhu, D. Zhang, W. Wang, et al.
A novel coronavirus from patients with pneumonia in China, 2019.
New Engl J Med, 382 (2020), pp. 727-733
[3.]
WHO.
Coronavirus disease (Covid-19) pandemic.
[4]
E. Andreano, et al.
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Proc Natl Acad Sci U S A, 118 (2021),
[5.]
A.J. Greaney, et al.
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.
Cell Host Microbe, 29 (2021), pp. 463-476
[6.]
J.F. Chan, K.H. Kok, Z. Zhu, et al.
Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan.
Emerg Microbes Infect, 9 (2020), pp. 221-236
[7.]
D. Gordon, G. Jang, M. Bouhaddou, et al.
A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing.
[8.]
F. Wu, S. Zhao, B. Yu, et al.
A new coronavirus associated with human respiratory disease in China.
Nature., 579 (2020), pp. 265-269
[9.]
T. Muramatsu, C. Takemoto, Y. Kim, et al.
SARS–CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity.
Proc Natl Acad Sci U S A, 113 (2016), pp. 12997-13002
[10.]
F.K. Yoshimoto.
The proteins of severe acute respiratory syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19.
Protein J, 39 (2020), pp. 198-216
[11.]
A.R. Fehr, S. Perlman.
Coronaviruses: an overview of their replication and pathogenesis.
Methods Mol Biol, 1282 (2015), pp. 1-23
[12.]
J. Ziebuhr, A.E. Gorbalenya, E.J. Snijder.
Virus-encoded proteinases and proteolytic processing in the Nidovirales.
J Gen Virol, 81 (2000), pp. 853-879
[13.]
C.C. Stobart, N.R. Sexton, H. Munjal, X. Lu, K.L. Molland, et al.
Chimeric exchange of coronavirus NSP5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity.
J Virol, 87 (2013), pp. 12611-12618
[14.]
X. Lu, Y. Lu, M.R. Denison.
Intracellular and in vitro-translated 27-kDa proteins contain the 3C-like proteinase activity of the coronavirus MHV-A59.
Virology., 222 (1996), pp. 375-382
[15.]
L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, et al.
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors.
Science., 368 (2020), pp. 409-412
[16.]
Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Y. Zhao, et al.
Structure of M pro from SARS-CoV-2 and discovery of its inhibitors.
Nature., 582 (2020), pp. 289-293
[17.]
N. Yashvardhini, A. Kumar, D.K. Jha.
Immunoinformatics identification of B- and T-cell epitopes in the RNA-dependent RNA polymerase of SARS-CoV-2.
Can J Infect Dis Med Microbiol, (2021),
[18.]
F. Madeira, Y. Park, J. Lee, et al.
The EMBL-EBI search and sequence analysis tools APIs in 2019.
Nucl Acids Res, 47 (2019), pp. W636-W641
[19.]
Y. Choi, et al.
PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels.
Bioinfo., 31 (2015), pp. 2745-2747
[20.]
E. Gasteiger, C. Hoogland, A. Gattiker, et al.
Protein identification and analysis tools on the ExPASy server.
Prot Proto Hand, (2005), pp. 571-607
[21.]
T. Ashok Kumar.
CFSSP: Chou and Fasman secondary structure prediction server.
Wide Spec, 1 (2013), pp. 15-19
[22.]
L. Kelley, S. Mezulis, C. Yates, M. Wass, et al.
The Phyre2 web portal for protein modeling, prediction and analysis.
Nat Proto, 10 (2015), pp. 845-858
[23.]
C.H.M. Rodrigues, D.E.V. Pires, D.B. Ascher.
DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability.
Nucl Acid Res, 46 (2018), pp. W350-W355
[24.]
Y. Kim, J. Ponomarenko, Z. Zhu, et al.
Immune epitope database analysis resource.
Nucl acid Res, 40 (2012), pp. W525-W530
[25.]
I.A. Doytchinova, D.R. Flower.
VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines.
BMC Bioinfo., 8 (2017), pp. 4
[26.]
I. Dimitrov, D.R. Flower, I. Doytchinova.
AllerTOP-a server for in silico prediction of allergens.
BMC Bioinfo, 14 (2013), pp. S4
[27.]
D. Benvenuto, M. Giovanetti, A. Ciccozzi, S. Spoto, S. Angeletti, M. Ciccozzi.
The 2019-new coronavirus epidemic: evidence for virus evolution.
J Med Virol, 92 (2020), pp. 455-459
[28.]
M.A. Wang, et al.
Temperature significant change COVID-19 transmission in 429 cities.
medRxiv, (2020),
[29.]
M.K. Roe, N.A. Junod, A.R. Young, D.C. Beachboard, C.C. Stobart.
Targeting novel structural and functional features of coronavirus protease nsp5 (3CLpro, Mpro) in the age of COVID-19.
[30.]
E.F. Donaldson, R.L. Graham, A.C. Sims, M.R. Denison, R.S. Baric.
Analysis of murine hepatitis virus strain A59 temperature-sensitive mutant TS-LA6 suggests that nsp10 plays a critical role in polyprotein processing.
J Virol, 81 (2007), pp. 7086-7098
[31.]
C.C. Stobart, A.S. Lee, X. Lu, M.R. Denison.
Temperature-sensitive mutants and revertants in the coronavirus nonstructural protein 5 protease (3CLpro) defne residues involved in long-distance communication and regulation of protease activity.
J Virol, 86 (2012), pp. 4801-4810
[32.]
H.L. Stokes, S. Baliji, C.G. Hui, S.G. Sawicki, S.C. Baker, et al.
A new cistron in the murine hepatitis virus replicase gene.
J Virol, 84 (2010), pp. 10148-10158
[33.]
F. Wu, S. Zhao, B. Yu, et al.
A new coronavirus associated with human respiratory disease in China.
Nature., 579 (2020), pp. 265-269
[34.]
W. Tai, L. He, X. Zhang, J. Pu, et al.
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.
Cell Mol Immunol, (2020), pp. 1-8
[35.]
N. Chen, et al.
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.
[36]
Q. Li, et al.
Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia.
New Engl J Med, 382 (2020), pp. 1199-1207
[37.]
M. Dangi, R. Kumari, R. Singh, et al.
Advanced in silico tools for designing of antigenic epitope as potential vaccine candidates against coronavirus.
Bioinfor Seq Struct Phylogeny, (2018), pp. 329-357
[38.]
C.L. Jr Slingluff, S. Lee, F. Zhao, et al.
A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
Clin Cancer Res, 19 (2013), pp. 4228-4238
[39.]
H. Toledo, A. Baly, O. Castro, et al.
A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.
Vaccine, 19 (2001), pp. 4328-4336
[40.]
A. Khan, D.M. Khan, S. Saleem, et al.
Phylogenetic analysis and structural perspectives of RNA-dependent RNA-polymerase inhibition from SARs-CoV-2 with natural products.
Interdis Sci Comput Life Sci, 12 (2020), pp. 335-348
[41.]
S.S. Chiou, Y.C. Fan, W.D. Crill, et al.
Mutation analysis of the cross-reactive epitopes of Japanese encephalitis virus envelope glycoprotein.
J Gen Virol, 93 (2012), pp. 1185-1192
[42.]
L. Du, Y. He, Y. Zhou, et al.
The spike protein of SARSCoV — a target for vaccine and therapeutic development.
Nat Rev Microbiol, 7 (2009), pp. 226-236
asdasdasd
Opciones de artículo
Herramientas
Material suplementario